Briefing.com uses cookies to store information on your computer that is essential to making the site work and to customizing the user experience. By using the site, you consent to the placement of these cookies. Read our cookie policy to learn more and how to withdraw your consent.     
You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • Google+
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >The Week Ahead for the IPO...
Story Stocks® Archive
Last Update: 24-Sep-18 09:50 ET
The Week Ahead for the IPO Market (VIOT)
The IPO market ended last week with a bang as tech companies Eventbrite (EB) and Farfetch (FTCH) shined. Both deals were up-sized, priced strongly, and opened for trading with sizable gains -- 57% and 35%, respectively. We feel that the success of these IPOs better reflects the true state of the IPO market, rather than the weaker pricings posted by the three China-based deals before it. This is further corroborated by the fact that this week, with as many as twelve deals lined up, will be perhaps the busiest of the year.

Monday, September 24:
  • No IPOs expected.

Tuesday, September 25:

  • Viomi Technology (VIOT): The China-based developer of an IoT home platform connecting a suite of complementary consumable products is expected to price its 11.4 mln ADS IPO within a range of $9-$11.

Wednesday, September 26:

  • Arco Platform (ARCE): The Brazil-based provider of educational content through printed and digital formats is expected to price its 11.1 mln ADS IPO within a range of $15.50-$17.50.
  • Capital Bancorp (CBNK): The bank holding company based in the Washington D.C. and Baltimore areas is expected to price its 2.2 mln share IPO within a range of $12.50-$14.50.
  • SurveyMonkey (SVMK): The provider of survey software products is expected to price its 13.5 mln share IPO within a range of $9-$11.
  • Entasis Therapeutics (ETTX): The clinical-stage biopharmaceutical company developing antibacterial products to treat serious infections is expected to price its 4.4 mln share IPO within a range of $16-$18.

Thursday, September 27:

  • Arvinas (ARVN): The biopharmaceutical company developing therapies to degrade disease-causing proteins is expected to price its 6.7 mln share IPO within a range of $14-$16.
  • LAIX, Inc. (LAIX): The China-based AI company creating products to popularize English learning is expected to price its 5.8 mln share IPO within a range of $11.50-$13.50.
  • Ra Medical Systems (RMED): The commercial-stage medical device company focused on treatment of vascular and dermatological diseases is expected to price its 3.3 mln share IPO within a range of $14-$16.
  • Sutro Biopharma (STRO): The clinical stage biopharma developing a variety of protein therapeutics for cancer and autoimmune disorders is expected to price its 5.0 mln share IPO within a range of $14-$16.
  • Urovant Sciences (UROV): The clinical-stage biopharmaceutical company developing therapies for urologic disorders is expected to price its 10.0 mln share IPO within a range of $14-$16.

Friday, September 28:

  • CooTek (CTK): The China-based mobile internet company developing a portfolio of applications is expected to price its 4.4 mln share IPO within a range of $12-$14.
  • Gritstone Oncology (GRTS): The immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types is expected to price its 6.1 mln share IPO within a range of $13-$15.
The IPO market ended last week with a bang as tech companies Eventbrite (EB) and Farfetch (FTCH) shined. Both deals were up-sized, priced strongly,
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Request a Demo
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Cookie Policy
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup